Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...